Barry S. Ticho, M.D., Ph.D., FACC

Barry S. Ticho, M.D., Ph.D., FACC

Chief Medical OfficeratStoke Therapeutics· In proxies 2022–2024

Pay in FY2024+50% from the year before · Stoke Therapeutics stock +109.7% the same year

Barry S. Ticho, M.D., Ph.D., FACC was paid $2.5M in FY2024 (Dec), up 50%. Stoke Therapeutics stock rose 109.7% that year.

Pay$100 in the stock at the end of FY21 → $46
Pay is from the Summary Compensation Table of each Stoke Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Stoke TherapeuticsPublic company · 4 yr
    • Chief Medical Officer2022 – Present · 4 yrStock in role +20%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?